Julie Axelrod was a laboratory technician until the age of 42 years, when he finally achieved his PhD and independence. He worked at the National Institutes of Health for most of his career. Among his early pioneering research achievements in applying chemical and biochemical approaches to neuroscience were the discoveries of the painkiller acetaminophen (Tylenol, Paracetamol) and the liver microsomal drug-metabolizing enzymes, and the establishment of catechol-O-methyltransferase as an important enzyme in catecholamine metabolism. He shared the Nobel Prize in Physiology or Medicine in 1970 for his discovery that the reuptake of noradrenaline (norepinephrine) into the nerve endings from which it was released represented a novel method of neurotransmitter inactivation. An important corollary was the finding that antidepressant drugs acted as inhibitors of this uptake process.
in 1935 and they had two sons, Paul and Alfred (born in 1946 and 1949, respectively), who survive him. Sally died in 1992.
After graduation he made a number of attempts to obtain a place to study medicine but was unsuccessful, in part because of the widespread Jewish quotas of those days. In hard economic times he was lucky to find a job as a laboratory technician, initially at New York University and subsequently at the New York City Public Health Department, Laboratory of Industrial Hygiene , where he devised methods for measuring the vitamin content of various foods. Although this was fairly routine work, he gained experience in devising ingenious new chemical analytical methods that was to stand him in good stead later. By attending night school, he obtained a Master's degree in chemistry at New York University in 1942. He held the laboratory job for some 10 years and might have stayed there for the rest of his working life. However, in 1946 the head of the laboratory, Dr George Wallace, asked Axelrod if he would like to work on a problem concerning the widely used painkillers acetanilide and phenacetin. Some people who used large quantities of these drugs developed a serious blood disorder, methaemoglobinaemia (in which haemoglobin is rendered ineffective in carrying oxygen). Wallace had been commissioned to perform research on this problem; he nominated Julie Axelrod and suggested that he discuss research strategy with Dr Bernard Brodie. Brodie at that time was a professor of pharmacology at New York University and had conducted a pioneering programme of research on the metabolism of anti-malarial drugs as part of the World War II effort.
RESEARCH WITH BERNARD BRODIE
In February 1946 Julie Axelrod met Bernard Brodie, a charismatic scientist who was to change Axelrod's career dramatically. For the first time he had met someone who could supply the intellectual and scientific challenges that had so far been lacking in his career. Brodie was a brilliant scientist and a pioneer of the application of chemical and biochemical techniques to the study of drug actions. He introduced Axelrod to the study of drug metabolism and they started to work on the then widely used painkiller acetanilide. Brodie invited Axelrod to work in his laboratory at the Goldwater Memorial Hospital in New York. An examination of the chemical structure of acetanilide suggested that it might be converted to the dye aniline, already known to be able to cause methaemoglobinaemia. Axelrod developed a simple assay for aniline in urine and plasma (1)*, and in keeping with the research practices of the time he took a large dose of acetanilide himself and was able to detect aniline in his urine. As he later described it: 'This was one of the most exhilarating experiences in my life, making an important new discovery' (41). In further studies in patients it was rapidly established that there was a direct correlation between blood levels of aniline and methaemoglobin (2) . However, Brodie and Axelrod also made the unexpected discovery that another major product of the metabolism of acetanilide was the hydroxylated product acetaminophen, which was itself also an analgesic (figure 1). In their 1948 paper, Axelrod's first scientific publication (2), they discussed the idea that acetaminophen might represent a safer drug than acetanilide because it did not carry the risk of methaemoglobinaemia. This indeed proved true, and acetaminophen (known more commonly in the US as Tylenol or in Europe as Paracetamol) subsequently became the most widely used painkiller in the world-although neither Axelrod nor Brodie received any share of the commercial gains and little recognition for a major scientific discovery. The discovery, however, convinced Axelrod that he wanted to tackle other challenging scientific problems: 'This was my first taste of research and I loved it. "The Fate of Acetanilide in Man" (2) was my first paper and I was determined to continue doing research' (41).
Brodie invited Axelrod to stay on in the Goldwater Memorial Hospital laboratory to study the fate of other analgesic drugs. Using similar methodology they showed that another popular painkiller, phenacetin, was also metabolized to acetaminophen (3) . Another analgesic drug, antipyrine, was found to be distributed like body water, and Axelrod showed that its disposition could be used as a way of measuring total body water (4).
In 1949 Axelrod joined Brodie in a move to the newly formed National Institutes of Health (NIH) in Washington, DC, where Brodie became Chief of the Laboratory of Chemical Pharmacology at the National Heart Institute, housed in Building 3 on the NIH campus. There followed a period of highly productive original research. As Axelrod described it (41): 'This became one of the most fertile research settings in the world. Among the scientists working in Building 3 in the early 1950's, more than half became members of the National Academy of Science, five became Nobel laureates, and three were appointed directors of the NIH. ' He began working on new problems, including the metabolism of caffeine (6) and studies of the metabolism of amphetamines and ephedrine. He found that the latter substance was metabolized by two pathways, demethylation and hydroxylation of the benzene ring (5). The amphetamines were metabolized by similar pathways and in addition there was deamination and conjugation (7).
MICROSOMAL DRUG-METABOLIZING ENZYMES
As more examples of drug metabolism began to be understood it was possible to see that a variety of common pathways applied to many different substances. Axelrod was stimulated to seek a better understanding of the enzymes involved, which were almost completely unknown at the time. He worked with a biochemist, Gordon Tomkins, to develop test-tube models for studying drug metabolism, initially using slices or homogenates of rabbit liver. By separating various subcellular fractions by centrifugation, Axelrod eventually found that drug-metabolizing enzymes were concentrated in the microsomal fraction, containing fragments of intracellular membranes. Furthermore, a supernatant fraction containing various soluble cofactors was also needed, with NADP as a crucial ingredient. Using amphetamine and ephedrine as the model substrates, Axelrod described a heat-labile enzyme activity in liver microsomes that required reduced NADP and oxygen to deaminate the amines (8, 9). Further studies revealed a family of liver microsomal enzymes responsible for many aspects of drug metabolism. These were later identified as members of a family of cytochromes of the P450 group. The liver microsomal drug-metabolizing enzymes are now recognized as key players in the metabolic disposition of many medically important drugs. Axelrod had had a vital role in pioneering another critically important field of pharmacological research.
RESEARCH ON CATECHOLAMINES
Although Axelrod by now was more than 40 years old and had published many important scientific papers, latterly in his own name without Brodie, he remained a research technician without a PhD. He grew increasingly impatient for a more independent role, free from the somewhat overpowering influence of his mentor. This was eventually solved by attending graduate courses at George Washington University and submitting some of his published papers as a doctoral thesis. In 1955, 42 years old, he received his PhD. At about this time he was recruited to the National Institute of Mental Health. Its first director, Seymour Kety, was an outstanding scientist and administrator; in his own research he made key contributions to measurement of blood flow in brain, and later to understanding the genetic basis of schizophrenia. Axelrod was recruited by the neurophysiologist Ed Evarts, head of the newly formed Laboratory of Clinical Sciences, which sought to bring together scientists from different disciplines in an early example of what was later to become known as the 'neuroscience' approach to brain research.
Axelrod began working on the metabolism of lysergic acid diethylamide (d-LSD), using the then novel technique of fluorescence measurements. Kety suggested another topic: the metabolism of adrenaline (epinephrine). At that time two Canadian scientists, Abram Hoffer and Humphrey Osmond, had proposed that adrenaline was metabolized abnormally in schizophrenic patients to the oxidation product adrenochrome, and that this substance might be responsible for the hallucinations and other psychotic symptoms of the illness. Axelrod tried unsuccessfully to identify an enzyme that could catalyse the conversion of adrenaline to adrenochrome. Instead he noted that a novel metabolic product of adrenaline had been described in the urine of patients with adrenal medullary tumours, which secreted large amounts of adrenaline. The metabolite was 3-methoxy-4-hydroxymandelic acid, also called vannilylmandelic acid (VMA). This suggested that adrenaline could both be deaminated (by the already known enzyme monoamine oxidase) and O-methylated. Axelrod sought to identify an enzyme capable of catalysing such a methylation step. As a result he discovered the novel enzyme catechol-O-methyltransferase (COMT), capable of methylating adrenaline, noradrenaline and dopamine and a wide range of other catechols (10, 11). He went on to demonstrate that the O-methylated metabolites of the catecholamines, namely metanephrine, normetanephrine and 3-methoxytyramine, were present in brain and peripheral tissues. The collaborative atmosphere of research at the NIH at that time contributed valuably to this research. The organic chemist Bernhard Witkop provided the reference compounds to identify the O-methylated metabolites; with Irwin Kopin, Axelrod was able to show the role of COMT in human catecholamine metabolism; and the chemist John Daly was another key collaborator. These discoveries led to a more complete understanding of the complex metabolism of the catecholamines-involving deamination, O-methylation, glycol formation and conjugation to glucuronides and sulphates.
The discovery of COMT prompted Axelrod to look for other methyltransferases; this research was greatly facilitated by the availability for the first time of a radiolabelled methyl donor, S-[ 14 C]adenosylmethionine-synthesized by Axelrod with a postdoctoral fellow, Donald Brown. Using this, Axelrod was able to identify histamine N-methyltransferase, phenylethanolamine-N-methyltransferase (the enzyme that coverts noradrenaline to adrenaline), tryptamine-N-methyltransferase, and a protein carboxyl methyltransferase (41).
Axelrod shared the 1970 Nobel Prize in Physiology or Medicine with Sir Bernard Katz FRS and Ulf von Euler (ForMemRS 1973) 'for their discoveries concerning the humoral transmitters in the nerve terminals and the mechanism for their storage, release and inactivation'. It was for new understanding of the latter that Axelrod gained the prize. When neurotransmitters are released from nerve cells they must be rapidly inactivated, and it was widely assumed that for the catecholamines this involved their degradation by COMT and other enzymes to other inert substances. It was known that released acetylcholine was rapidly degraded in this way by the enzyme acetylcholinesterase. However, Axelrod discovered a completely novel mechanism for the inactivation of neurotransmitters, involving their recapture by the nerves from which they were released.
It was not until tritium-labelled radioactive catecholamines of high specific radioactivity became available in the late 1950s that experiments could be performed with quantities of monoamine small enough to mimic the very low concentrations of adrenaline or noradrenaline normally encountered in body fluids. Axelrod was able to use [ 3 H]adrenaline that Seymour Kety had commissioned for work on the adrenochrome hypothesis. When the first experiments were performed, they yielded an unexpected result. Although in laboratory animals most of the injected dose of labelled catecholamine was rapidly metabolized (mainly by COMT), a substantial proportion of the injected radiolabelled monoamine (30-40%) was removed from the circulation by a rapid uptake into tissues, where it remained unchanged for several hours, long after the physiological effects had waned (12) . Similar findings were later made with [ 3 H]noradrenaline (1). A key observation was that the uptake of [ 3 H]noradrenaline into the heart was virtually eliminated in animals in which the sympathetic innervation had been destroyed by previous surgical removal of the superior cervical ganglion (15) . Hertting and Axelrod (16) showed that [ 3 H]noradrenaline taken up into tissues could be released by stimulation of the sympathetic nerves, and this led them to propose that the reuptake of noradrenaline by the same nerves from which it had been released might represent a novel mechanism for inactivating this neurotransmitter. Direct proof that noradrenaline uptake occurred into sympathetic nerves was later obtained by electron microscope autoradiographs of rat pineal gland (which has a rich sympathetic innervation) after the administration of [ 3 H]noradrenaline, showing the localization of radioactivity in sympathetic nerve terminals (20) .
Soon after the discovery of catecholamine uptake, further research in the Axelrod laboratory demonstrated that the then newly discovered tricylic antidepressant drugs were potent inhibitors of noradrenaline uptake (19) , as was the psychostimulant drug cocaine (17) . The radiolabelled catecholamines did not penetrate into the brain because of their inability to cross the blood-brain barrier after systemic injection. This problem was subsequently circumvented by a French visitor to the laboratory, Jacques Glowinski, who injected [ 3 H]noradrenaline directly into the ventricular system of the rat brain. Glowinski and Axelrod (22) showed that clinically effective antidepressant drugs inhibited the uptake of labelled catecholamine in the brain in the same way as they did in peripheral sympathetic nerves. These discoveries had a profound impact on understanding the hitherto obscure mechanism of action of tricylic antidepressant drugs and on the subsequent development of improved antidepressant drugs. Work in other laboratories later showed that the reuptake concept had wide applicability to other neurotransmitter mechanisms, with the discovery of similar uptake mechanisms involved in inactivating serotonin, dopamine, glutamate and ȍ-aminobutyric acid (GABA). The serotonin uptake system proved particularly important because it became the target of today's generation of antidepressant drugs, the so-called 'serotonin-selective reuptake inhibitors' (SSRIs), exemplified by fluoxetine (Prozac).
THE PINEAL GLAND AND MELATONIN
The pineal gland is situated above the brain and receives a dense innervation from the peripheral sympathetic nervous system. The secretion of the hormone melatonin from the pineal is partly controlled by the light-dark cycle, and in seasonal breeding mammals this hormone has a key role in reproductive function. As melatonin is a methylated product of serotonin it drew Axelrod's attention and he began a series of studies on this small organ (in the rat it weighs less than 1 mg), which became a key focus for his laboratory for the rest of the 1960s and for much of the 1970s, involving many of the talented visiting fellows who flocked to work with him at that time.
The availability of radiolabelled S-adenosylmethionine was a key tool. Axelrod showed that incubating pineal extracts with this together with N-acetylserotonin led to the formation of radiolabelled melatonin. He went on to identify and purify the melatonin-forming enzyme, hydroxyindole-O-methyltransferase (HIOMT) (13) , and later identified the serotonin Nacetyltranferase that formed N-acetylserotonin (NAT) (14) (figure 2).
Attention then focused on the mechanisms involved in the control of melatonin synthesis in the pineal and its daily rhythm. Axelrod's students Richard Wurtman and Solomon Snyder were closely involved in the initial studies. With Axelrod, Wurtman explored the role of the sympathetic nervous system in light-induced suppression of melatonin synthesis (21). Snyder showed that there was daily rhythm in the serotonin content of the pineal, varying inversely with that of melatonin. The serotonin rhythm was abolished in animals exposed to constant light, but it persisted in animals kept in the dark or in blinded animals (24) . These results indicated that there was an endogenous diurnal rhythm that was controlled by light. The endogenous rhythm and the effects of light were abolished if the sympathetic nerves to the pineal were cut (23, 25) , indicating that the rhythm originated in the brain. With Michael Brownstein, Axelrod found evidence for a daily rhythm in the activity of sympathetic nerves, indicated by a diurnal fluctuation in their noradrenaline content (33) . With other postdoctoral fellows, Zatz and Romero, Axelrod showed that noradrenaline acted on ȋ-adrenoceptors in the pineal to activate the synthesis of the enzyme serotonin N-acetyltransferase, which in turn controlled melatonin synthesis (34, 38) . This was one of the first examples of the neural control of gene expression, involving rapid and dramatic alterations in the rates of synthesis of gene products. It was remarkable how much fundamental biological information Axelrod was able to generate from work on so small a gland, by a combination of technical virtuosity and great ingenuity in experimental design.
A second series of experiments demonstrated the control of the expression of another enzyme, tyrosine hydroxylase, by neural activity. With Hans Thoenen and others, Axelrod showed that increased activity in the presynaptic sympathetic nerves to the adrenal medulla led to an increased synthesis of this key enzyme in catecholamine biosynthesis (27, 29) . The changes in tyrosine hydroxylase involved alterations in de novo protein synthesis (28) , indicating that this was another example of the trans-synaptic control of gene expression (30) .
Axelrod continued to invent novel enzymatic-isotopic assays for biological amines. With such an assay he and Perry Molinoff were able to demonstrate the presence of the tyramine derivative octopamine in sympathetic nerves (26) and to study its turnover (31). With Juan Saavedra he devised sensitive assays for tryptamine and its N-methyl derivatives and used these to study these amines in the brain (32). Other work demonstrated that some brain regions contained appreciable amounts of adrenaline as well as noradrenaline (36) . In a technical tour de force he was able to demonstrate the existence of multiple biologically active amines in a single neuron from Aplysia (35) . With Stephen Paul he applied the same methodology to the measurement and study of an entirely different chemical class, the catechol oestrogens in brain (37) .
Late in his career Axelrod became interested in the neuropharmacology of cannabis. He contributed to the discovery of the first naturally occurring cannabinoid, anandamide (Narachidonylethanolamine) (39) and undertook some of the early studies of its properties in vivo (40) .
THE AXELROD LABORATORY Julie Axelrod described himself as a 'late blooming biochemical neuroscientist' (41) and he was indeed a classic example of someone whose independent scientific career started late. Despite this he worked as a research scientist for almost 50 years, 46 of which were spent at the NIH. I was privileged to work in his laboratory in 1964-65 at a time when visiting scientists from all over the world had begun to join the laboratory. We were among the first of his many postdoctoral fellows, and Julie continued to take visiting postdoctoral fellows for another 30 years or more. Life was hectic but very enjoyable in the Axelrod laboratory; Julie was full of more ideas than any of us could handle and we interacted often with him. He had a very informal style of leadership: letting young people develop their own projects and ideas, and always ready to provide positive encouragement. He conveyed an infectious enthusiasm for the discovery process; research for him was fun-and his students came to view it in the same way. Julie Axelrod was a genuinely creative experimental scientist. He did not like statistics or complex mathematical models, preferring the simple well-designed experiment that gave a clear-cut answer. He would say, 'If the difference between the two groups is so small that you need a statistical test to prove its significance, then it might not be a very important difference.' He had the knack of getting to the heart of complex problems-and knowing how to design the right methods and experiments to solve them. He was always a bench scientist. Every day he would conduct some experiment of his own, and would often stand in front of the radioactivity scintillation counter impatient to see the results. He eschewed an office and instead positioned his own desk next to the bench where the laboratory balance was located. Sooner or later everyone had to weigh something, so he would have the opportunity to find out what each person was doing that day-and maybe offer them his own thoughts.
He was a superb writer, avoiding complex language where something simpler would be clearer, and putting great effort into the process. He would sit with each of his students to write their papers, not correcting a pre-existing draft but writing the manuscript together from the beginning.
Julie received many offers of advancement to more to important positions in academia or to take on greater administrative responsibilities at the NIH. He refused all such offers in favour of remaining an active experimentalist.
He was a quiet, self-effacing, mild-mannered man with a good sense of humour. I never saw him get angry. He was always interested in his students and helped them greatly in their further careers. The experience of working with Julie proved to be a starting point for a generation of scientists working in the then new fields of neurochemistry and neuropharmacology. The important influence that mentors of genius have is graphically described by Robert Kanigel (Kanigel 1993) , who gives in more detail the influence that Brodie had on Julie Axelrod, and that Julie in turn had on his 'apprentices'. The Axelrod 'Diaspora' continues to share a common and universal affection for their mentor. Julie was constantly interested and solicitous of the members of his extended scientific family, and we will all sorely miss him.
Julie's humility and genius are summarized by his statement (Snyder 2005 ):
I soon learned that it did not require a great brain to do original research. One must be highly motivated, exercise good judgment, and have intelligence, imagination, determination and a little luck. … One of the most important qualities in doing research, I found, was to ask the right question at the right time. I learned that it takes the same effort to work on an important problem as on a pedestrian or trivial one. When opportunities came, I made the right choices.
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